Dermatitis News and Research RSS Feed - Dermatitis News and Research

Dermatitis is an infection of the skin. The skin may become itchy and progress to a bumpy red rash that may become tender. There may also be pus-filled blisters that are usually found surrounding hair follicles.
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Cipher acquires worldwide rights to three products from Astion

Cipher acquires worldwide rights to three products from Astion

Cipher Pharmaceuticals Inc. today announced it has strengthened its product pipeline by acquiring the worldwide rights to three products from Astion Pharma, a Denmark-based specialty pharmaceutical company. [More]
Changes to DNA sequence associated with peanut allergy

Changes to DNA sequence associated with peanut allergy

Research funded by the National Institutes of Health suggests that changes in a small region of chromosome 6 are risk factors for peanut allergy in U.S. children of European descent. The genetic risk area is located among two tightly linked genes that regulate the presentation of allergens and microbial products to the immune system. This study is the first to use a genome-wide screening approach in patients with well-defined food allergy to identify risks for peanut allergy. [More]
Hand hygiene increases incidence of dermatitis among healthcare workers

Hand hygiene increases incidence of dermatitis among healthcare workers

A new study from The University of Manchester has revealed that the incidence of dermatitis has increased 4.5 times in health care workers following increased hand hygiene as a drive to reduce infections such as MRSA has kicked in. [More]
CNIO researchers identify new mechanism that influences differentiation of keratinocytes

CNIO researchers identify new mechanism that influences differentiation of keratinocytes

The formation of human skin involves a cascade of biochemical signals, which are not well understood. However, they are very important since their failure may cause diseases, such as Atopic Dermatitis and skin cancers, which affect more than 25% of the human population. [More]
EMA accepts Praluent (alirocumab) MAA for review

EMA accepts Praluent (alirocumab) MAA for review

Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia. [More]
Two new ODYSSEY trials meet primary efficacy endpoints

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints. [More]
Fat cells below skin help protect from bacteria, say researchers

Fat cells below skin help protect from bacteria, say researchers

When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the University of California, San Diego School of Medicine report the surprising discovery that fat cells below the skin help protect us from bacteria. [More]
FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic. [More]
First-line dacomitinib may improve advanced NSCLC survival

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. [More]
Oncologists examine efficacy of rose bengal against cancer

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma. [More]
University of Chicago obtains GFFS certification from Gluten Intolerance Group

University of Chicago obtains GFFS certification from Gluten Intolerance Group

The University of Chicago has received certification from the Gluten Intolerance Group's Gluten-Free Food Service (GFFS) Accreditation Program for its medical center and campus food service operations. The designation makes UChicago one of three medical centers in the United States to carry the accreditation, and the only academic institution to do so for both its hospital and campus facilities. [More]
Exposure to peanut proteins in household dust may trigger peanut allergy

Exposure to peanut proteins in household dust may trigger peanut allergy

Exposure to peanut proteins in household dust may be a trigger of peanut allergy, according to a study published today in the Journal of Allergy and Clinical Immunology. [More]
New anti-cancer drug may protect normal cells against radiation

New anti-cancer drug may protect normal cells against radiation

Although radiation treatments have become much more refined in recent years, it remains a challenge to both sufficiently dose the tumor while sparing the surrounding tissue. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response. [More]
People with celiac disease have reactions to non-gluten wheat proteins

People with celiac disease have reactions to non-gluten wheat proteins

Although gluten-free foods are trendy among the health-conscious, they are necessary for those with celiac disease. But gluten, the primary trigger for health problems in these patients, may not be the only culprit. Scientists are reporting in ACS' Journal of Proteome Research that people with the disease also have reactions to non-gluten wheat proteins. The results could help scientists better understand how the disease works and could have implications for how to treat it. [More]
Adults with eczema at greater risk of accidental bone fractures, other injuries

Adults with eczema at greater risk of accidental bone fractures, other injuries

Intense itching and dry, irritable skin aren't the only problems adults with eczema face. They are at greater risk of accidental bone fractures and other injuries, a new Northwestern Medicine® study has found. [More]
Vanda reports total revenues of $14.8 million for third quarter 2014

Vanda reports total revenues of $14.8 million for third quarter 2014

Vanda Pharmaceuticals Inc., today announced financial and operational results for the third quarter ended September 30, 2014. [More]
Growth factor boosts natural defence against auto-immune diseases

Growth factor boosts natural defence against auto-immune diseases

Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes or multiple sclerosis. A molecule called insulin-like growth factor-1 (IGF-1) boosts the body's natural defence against this 'friendly fire', scientists at the European Molecular Biology Laboratory in Monterotondo, Italy, have found. [More]
Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. [More]